The filing signals a complete transformation of BFNH under new control. Traders should monitor for further details on the oil and gas strategy, potential asset acquisitions, and any financing or capital structure changes. The low valuation and OTC listing suggest high risk and speculative interest.
Price Chart
Executive Summary
BioForce Nanosciences Holdings (BFNH) filed an 8-K reporting a change in control where director Merle Ferguson sold his 79.65% stake (26.7M shares) to Nexus Capital Investments for $400,000. Simultaneously, both co-CEOs and a VP resigned, a new director was appointed, and the company announced it is pivoting from vitamin supplements to the oil and gas industry. This represents a complete overhaul of ownership, management, and business strategy for this micro-cap OTC stock.
Key Facts
- On April 15, 2026, Merle Ferguson sold 26,700,000 shares (79.65% of outstanding common stock) to Nexus Capital Investments, Inc. for $400,000, resulting in a change in control.
- On June 17, 2026, co-CEOs Steven Gagnon and John LaViolette, and VP Sasha Shapiro resigned; the board accepted with no conflicts.
- On June 15, 2026, Scott Mager was appointed as a director.
- On June 17, 2026, Richard Kaiser (existing CFO, Secretary, and Director) was appointed interim CEO.
- The board now consists of Merle Ferguson, Richard Kaiser, and Scott Mager.
- The company announced it is changing its business operations from the vitamin supplement industry to the oil and gas industry and is evaluating opportunities.
Financial Impact
Change in control at $400,000 for 79.65% of shares implies a pre-transaction market capitalization of approximately $502,000. No revenue, earnings, or other financial figures were disclosed in the filing.
Risk Factors
- Execution risk of the pivot from vitamin supplements to oil and gas, an unrelated industry.
- Extremely low market capitalization (~$500k) and OTC listing limit liquidity and institutional interest.
- Management concentration with Richard Kaiser holding multiple officer roles (interim CEO, CFO, Secretary).
- Lack of financial disclosure makes it impossible to assess the existing business health.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001091818-26-000084 |
| Document: 0001091818-26-000084-index-headers.html | 0001091818-26-000084 |
| Document: 0001091818-26-000084-index.html | 0001091818-26-000084 |
| Document: 0001091818-26-000084.txt | 0001091818-26-000084 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | 8-K | $8.89 | awaiting T+20 | — | $8.19 (−7.87%) |
Sep 4, 2026 7w ago | 8-K | $6.10 $7.01 | ▼ −14.92% | ▼ −14.07% | $8.19 (−34.26%) |
Aug 18, 2026 9w ago | 8-K | $3.84 $10.01 | ▲ +160.68% | ▲ +161.67% | $8.19 (+113.28%) |
Aug 14, 2026 10w ago | 8-K | $3.40 $9.71 | ▲ +185.59% | ▲ +187.58% | $8.19 (+140.88%) |
Jul 7, 2026 15w ago | 8-K | $2.02 $1.85 | ▼ −8.42% | ▼ −11.57% | $8.19 (+305.45%) |
Jul 1, 2026 16w ago | 8-K | $1.69 $1.90 | ▲ +12.43% | ▲ +12.97% | $8.19 (+384.62%) |
Jun 18, 2026 18w ago | 8-K | $1.79 $1.50 | ▼ −16.20% | ▼ −15.58% | $8.19 (+357.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers